CLYM CLIMB BIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, CLIMB BIO INC reported revenue of n/a, net income of −$13.5M and diluted EPS of −$0.18; for the fiscal year ended December 2025 revenue was n/a.
CLYM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$67.9M, net income −$59.9M (margin n/a), EPS −$0.88
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$82.0M, net income −$73.9M (margin n/a), EPS −$1.53
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$40.3M, net income −$35.1M (margin n/a), EPS −$1.30
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$45.1M, net income −$45.2M (margin n/a), EPS −$1.72
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$35.7M, net income −$47.5M (margin n/a), EPS −$4.24
CLYM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$13.5M, EPS −$0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.7M, EPS −$0.20
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$17.5M, EPS −$0.25
- Quarter ended Sep 30, 2025: revenue n/a, net income −$12.9M, EPS −$0.19
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.67M, EPS −$0.13
- Quarter ended Mar 31, 2025: revenue n/a, net income −$20.8M, EPS −$0.31
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$8.42M, EPS $0.47
- Quarter ended Sep 30, 2024: revenue n/a, net income −$8.90M, EPS −$0.13
- Quarter ended Jun 30, 2024: revenue n/a, net income −$54.9M, EPS −$1.81
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.70M, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.64M, EPS −$0.12
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.97M, EPS −$0.15
- Quarter ended Jun 30, 2023: revenue n/a, net income −$5.22M, EPS −$0.19
- Quarter ended Mar 31, 2023: revenue n/a, net income −$22.3M, EPS −$0.84
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.76M, EPS −$0.48
- Quarter ended Sep 30, 2022: revenue n/a, net income −$9.68M, EPS −$0.37
- Quarter ended Jun 30, 2022: revenue n/a, net income −$14.6M, EPS −$0.37
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.2M, EPS −$0.50
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$10.5M, EPS $5.27
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.62M, EPS −$0.70
CLYM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$54.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$15.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$20.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$37.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$36.1M, share buybacks n/a
CLYM balance sheet
- Jun 30, 2026: cash $44.1M, total assets $246M, total liabilities $6.75M, shareholders' equity $240M
- Mar 31, 2026: cash $8.36M, total assets $152M, total liabilities $4.29M, shareholders' equity $148M
- Dec 31, 2025: cash $35.7M, total assets $168M, total liabilities $7.27M, shareholders' equity $160M
- Sep 30, 2025: cash $25.8M, total assets $182M, total liabilities $5.30M, shareholders' equity $177M
- Jun 30, 2025: cash $22.7M, total assets $192M, total liabilities $6.62M, shareholders' equity $186M
- Mar 31, 2025: cash $29.0M, total assets $201M, total liabilities $7.36M, shareholders' equity $193M
- Dec 31, 2024: cash $87.2M, total assets $217M, total liabilities $5.31M, shareholders' equity $212M
- Sep 30, 2024: cash $146M, total assets $222M, total liabilities $3.42M, shareholders' equity $219M
Is CLYM profitable?
No. CLIMB BIO INC lost $57.6M over the last four quarters.
What is CLYM's EPS?
Diluted earnings per share over the last four quarters were −$0.82; −$0.18 in the latest quarter.